← Back to headlines
Rezolute Awaits FDA Feedback on Congenital Hyperinsulinism Treatment
The medical device company is awaiting regulatory input regarding clinical data for its minimally invasive treatment for a rare pediatric metabolic disorder.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
